Tirzepatide is the active ingredient in Zepbound. This medication is used for weight management, and its counterpart is Mounjaro, which is used for type 2 diabetes treatment.
Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps the body regulate blood sugar and control appetite. The safety of these medications is currently in question as there are people who develop gastroparesis, vision loss, ileus, bowel obstruction, and persistent vomiting after using them.
There are over 1,300 pending lawsuits against the manufacturers of GLP-1 RA medications. The plaintiffs are claiming that Novo Nordisk and Eli Lilly didn't warn them about the severe health risks the injections pose. If you’re suffering from gastroparesis, vision loss, or bowel obstruction, reach out to our experts, and they'll evaluate your case free of charge.